Argenx To Acquire Forte Biosciences For $77 Per Share Cash, Valuing Deal At ~$2.2B, Adding CD122-Targeting FB102 With Vitiligo And Celiac Data
Transaction builds on argenx’s prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology that can fuel long-term growthFB102 Phase 1b studies in vitiligo and celiac
Argenx is buying a smaller company called Forte for $2.2 billion to get a new medicine (FB102) that might help people with skin and stomach diseases. When a big company buys a smaller one to get new treatments, it shows they believe in growing their business and think the medicine could be valuable.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.